28-Aug-2026
Business Wire (Mon, 10-Aug 9:00 AM ET)
ImmunityBio’s Revenue Jump and Global Expansion Highlight a Turning Point Despite Steep Losses
Market Chameleon (Tue, 4-Aug 3:42 AM ET)
Business Wire (Tue, 4-Aug 7:30 AM ET)
Business Wire (Wed, 29-Jul 6:45 PM ET)
ImmunityBio’s NK-Cell Platform: How IBRX Stands Out in the Race for Next-Gen Cancer Therapy
Market Chameleon (Mon, 8-Jun 5:26 AM ET)
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Globe Newswire (Mon, 8-Jun 9:01 AM ET)
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
Globe Newswire (Wed, 3-Jun 9:28 AM ET)
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Business Wire (Mon, 1-Jun 1:52 PM ET)
Market Chameleon (Tue, 19-May 6:19 AM ET)
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of August 28, 2026, IBRX stock price declined to $8.05 with 7,511,361 million shares trading.
IBRX has a beta of 1.56, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.03 to the broad based SPY ETF.
IBRX has a market cap of $8.53 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $51 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.00.
In the last 3 years, IBRX traded as high as $12.43 and as low as $1.25.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
IBRX has outperformed the market in the last year with a price return of +245.5% while the SPY ETF gained +19.7%. IBRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.3% and +6.3%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
IBRX support price is $8.09 and resistance is $8.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.